Key genetic alterations driving pancreas cancer, including mutations in KRAS, TP53, CDKN2A, and SMAD4, are incorporated into various GEMMs to model the disease initiation and progression (84–86). The gene discussed is TP53; the disease is pancreatic neoplasm.